THE C-TERMINUS OF TISSUE FACTOR PATHWAY INHIBITOR IS ESSENTIAL TO ITS ANTICOAGULANT ACTIVITY

被引:113
作者
NORDFANG, O
BJORN, SE
VALENTIN, S
NIELSEN, LS
WILDGOOSE, P
BECK, TC
HEDNER, U
机构
[1] Novo Nordisk A/S, DK 2820 Gentofte
关键词
D O I
10.1021/bi00107a002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tissue factor pathway inhibitor (TFPI) from different cell lines shows up to 15-fold differences in the ratio of anticoagulant to chromogenic activity. The anticoagulant activity was dependent on the purification procedure used and it was possible to isolate two fractions of recombinant TFPI. Only one of these fractions showed anticoagulant activity comparable with TFPI from normal human plasma, and Western blotting showed that the low-activity fraction did not react with an antibody raised against a peptide of TFPI located near the C-terminal. Analysis by mass spectroscopy of peptides from V8 protease digests showed that C-terminal amino acids could only be identified from the high-activity form, while heterologous fragmentation had taken place in the form with low anticoagulant activity. Previously published studies on TFPI have been performed using material of low anticoagulant activity compared with plasma TFPI, and we suggest that these studies have been performed with material degraded in the C-terminus.
引用
收藏
页码:10371 / 10376
页数:6
相关论文
共 50 条
[41]   The C-terminus is essential for the stability of the mycobacterial channel protein MspA [J].
Pavlenok, Mikhail ;
Nair, Rashmi Ravindran ;
Hendrickson, R. Curtis ;
Niederweis, Michael .
PROTEIN SCIENCE, 2024, 33 (03)
[42]   Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo [J].
Liang, Wang ;
Cheng, Juan ;
Liu, Rui ;
Wang, Ji-ping ;
Mu, Jin-gui ;
Wang, Qing-hua ;
Wang, Hui-jun ;
Ma, Duan .
PEPTIDES, 2009, 30 (12) :2330-2336
[43]   Heparin-tissue factor pathway inhibitor complexes: Anticoagulant and pharmacokinetic properties [J].
Wun, TC ;
Palmier, MO .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1998, 4 (03) :179-188
[44]   Poor anticoagulant response to tissue factor pathway inhibitor in patients with venous thrombosis [J].
Tardy-Poncet, B ;
Tardy, B ;
Laporte, S ;
Mismetti, P ;
Amiral, J ;
Piot, M ;
Reynaud, J ;
Campos, L ;
Decousus, H .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :507-510
[45]   Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat [J].
Shirk, RA ;
Zhang, ZM ;
Winneker, RC .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 94 (04) :361-368
[46]   Tissue factor and tissue factor pathway inhibitor activity in isolated human islets [J].
Pitroda, Sean ;
Turturro, Michael ;
Connors, Mathew ;
Garfinkel, Marc ;
Hall, Connie .
DIABETES, 2006, 55 :A445-A446
[47]   THE C-TERMINUS OF MITOSIN IS ESSENTIAL FOR ITS NUCLEAR-LOCALIZATION, CENTROMERE/KINETOCHORE TARGETING, AND DIMERIZATION [J].
ZHU, XL ;
CHANG, KH ;
HE, DC ;
MANCINI, MA ;
BRINKLEY, WR ;
LEE, WH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (33) :19545-19550
[48]   Tissue factor pathway inhibitor as a universal anticoagulant for use in clinical laboratory tests [J].
Tsuji, R ;
Tatsumi, N ;
Hino, M ;
Nishioka, T ;
Takubo, T .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (03) :165-174
[49]   Tissue factor pathway inhibitor activity in severe sepsis [J].
Creasey, AA ;
Reinhart, K .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S126-S129
[50]   TISSUE FACTOR PATHWAY INHIBITOR ACTIVITY IN PATIENTS WITH IDDM [J].
LEURS, PB ;
VANOERLE, R ;
HAMULYAK, K ;
WOLFFENBUTTEL, BHR .
DIABETES, 1995, 44 (01) :80-84